352 related articles for article (PubMed ID: 30604401)
1. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
2. Radiogallium Complex-Conjugated Bifunctional Peptides for Detecting Primary Cancer and Bone Metastases Simultaneously.
Ogawa K; Yu J; Ishizaki A; Yokokawa M; Kitamura M; Kitamura Y; Shiba K; Odani A
Bioconjug Chem; 2015 Aug; 26(8):1561-70. PubMed ID: 26087328
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Biological Evaluation of
Liu F; Liu T; Xu X; Guo X; Li N; Xiong C; Li C; Zhu H; Yang Z
Mol Pharm; 2018 Feb; 15(2):619-628. PubMed ID: 29278911
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Evaluation of ¹⁸F-SiFAlin-Modified TATE: A Potential Challenge for ⁶⁸Ga-DOTATATE, the Clinical Gold Standard for Somatostatin Receptor Imaging with PET.
Niedermoser S; Chin J; Wängler C; Kostikov A; Bernard-Gauthier V; Vogler N; Soucy JP; McEwan AJ; Schirrmacher R; Wängler B
J Nucl Med; 2015 Jul; 56(7):1100-5. PubMed ID: 25977461
[TBL] [Abstract][Full Text] [Related]
5. DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.
Li WP; Lewis JS; Kim J; Bugaj JE; Johnson MA; Erion JL; Anderson CJ
Bioconjug Chem; 2002; 13(4):721-8. PubMed ID: 12121126
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [
Xie Q; Liu T; Ding J; Zhou N; Meng X; Zhu H; Li N; Yu J; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3129-3140. PubMed ID: 33630145
[TBL] [Abstract][Full Text] [Related]
7. Development of novel radiogallium-labeled bone imaging agents using oligo-aspartic acid peptides as carriers.
Ogawa K; Ishizaki A; Takai K; Kitamura Y; Kiwada T; Shiba K; Odani A
PLoS One; 2013; 8(12):e84335. PubMed ID: 24391942
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Investigation into the Influence of Net Charge on the Biological Distribution of Radiometalated Peptides Using [
Raheem SJ; Salih AK; Garcia MD; Sharpe JC; Toosi BM; Price EW
Bioconjug Chem; 2023 Mar; 34(3):549-561. PubMed ID: 36800496
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
10.
Liu F; Zhu H; Yu J; Han X; Xie Q; Liu T; Xia C; Li N; Yang Z
Tumour Biol; 2017 Jun; 39(6):1010428317705519. PubMed ID: 28618966
[TBL] [Abstract][Full Text] [Related]
11. Next Generation of SiFAlin-Based TATE Derivatives for PET Imaging of SSTR-Positive Tumors: Influence of Molecular Design on In Vitro SSTR Binding and In Vivo Pharmacokinetics.
Litau S; Niedermoser S; Vogler N; Roscher M; Schirrmacher R; Fricker G; Wängler B; Wängler C
Bioconjug Chem; 2015 Dec; 26(12):2350-9. PubMed ID: 26420336
[TBL] [Abstract][Full Text] [Related]
12. Radiosynthesis and Preclinical Evaluation of
Maschauer S; Heilmann M; Wängler C; Schirrmacher R; Prante O
Bioconjug Chem; 2016 Nov; 27(11):2707-2714. PubMed ID: 27715017
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of a dual sstr2 and integrin α
Liu B; Zhang Z; Wang H; Yao S
Bioorg Med Chem; 2019 Nov; 27(21):115094. PubMed ID: 31540828
[TBL] [Abstract][Full Text] [Related]
14. Correlation of Somatostatin Receptor-2 Expression with Gallium-68-DOTA-TATE Uptake in Neuroblastoma Xenograft Models.
Zhang L; Vines DC; Scollard DA; McKee T; Komal T; Ganguly M; Do T; Wu B; Alexander N; Vali R; Shammas A; Besanger T; Baruchel S
Contrast Media Mol Imaging; 2017; 2017():9481276. PubMed ID: 29097943
[TBL] [Abstract][Full Text] [Related]
15. A Novel Small Cyclic Peptide-Based
Liu H; Hu M; Deng J; Zhao Y; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Mol Pharm; 2022 Jan; 19(1):138-147. PubMed ID: 34910492
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution and first clinical results of
Ilhan H; Lindner S; Todica A; Cyran CC; Tiling R; Auernhammer CJ; Spitzweg C; Boeck S; Unterrainer M; Gildehaus FJ; Böning G; Jurkschat K; Wängler C; Wängler B; Schirrmacher R; Bartenstein P
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):870-880. PubMed ID: 31492994
[TBL] [Abstract][Full Text] [Related]
17. Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE.
Velikyan I; Xu H; Nair M; Hall H
Nucl Med Biol; 2012 Jul; 39(5):628-39. PubMed ID: 22336375
[TBL] [Abstract][Full Text] [Related]
18. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical.
Lopez-Rodriguez V; Gaspar-Carcamo RE; Pedraza-Lopez M; Rojas-Calderon EL; Arteaga de Murphy C; Ferro-Flores G; Avila-Rodriguez MA
Nucl Med Biol; 2015 Feb; 42(2):109-14. PubMed ID: 25316595
[TBL] [Abstract][Full Text] [Related]
19. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers.
Persson M; Madsen J; Østergaard S; Ploug M; Kjaer A
Nucl Med Biol; 2012 May; 39(4):560-9. PubMed ID: 22172391
[TBL] [Abstract][Full Text] [Related]
20. Preparation and evaluation of a radiogallium complex-conjugated bisphosphonate as a bone scintigraphy agent.
Ogawa K; Takai K; Kanbara H; Kiwada T; Kitamura Y; Shiba K; Odani A
Nucl Med Biol; 2011 Jul; 38(5):631-6. PubMed ID: 21718937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
